TREM2 is associated with advanced stages and inferior prognosis in oral squamous cell carcinoma

• Verfasst von: Struckmeier, Ann-Kristin [VerfasserIn]
• Verfasst von: Radermacher, Anne [VerfasserIn]
• Verfasst von: Fehrenz, Michael [VerfasserIn]
• Verfasst von: Alansary, Dalia [VerfasserIn]
• Verfasst von: Wartenberg, Philipp [VerfasserIn]
• Verfasst von: Wagner, Mathias [VerfasserIn]
• Verfasst von: Scheller, Anja [VerfasserIn]
• Verfasst von: Heß, Jochen [VerfasserIn]
• Verfasst von: Moratin, Julius [VerfasserIn]
• Verfasst von: Freudlsperger, Christian [VerfasserIn]
• Verfasst von: Hoffmann, Jürgen [VerfasserIn]
• Verfasst von: Thurner, Lorenz [VerfasserIn]
• Verfasst von: Roemer, Klaus [VerfasserIn]
• Verfasst von: Freier, Kolja [VerfasserIn]
• Verfasst von: Horn, Dominik [VerfasserIn]
• Titel: TREM2 is associated with advanced stages and inferior prognosis in oral squamous cell carcinoma
• Verf.angabe: Ann-Kristin Struckmeier, Anne Radermacher, Michael Fehrenz, Dalia Alansary, Philipp Wartenberg, Mathias Wagner, Anja Scheller, Jochen Hess, Julius Moratin, Christian Freudlsperger, Jürgen Hoffmann, Lorenz Thurner, Klaus Roemer, Kolja Freier and Dominik Horn
• E-Jahr: 2022
• Jahr: 24 September 2022
• Umfang: 14 S.
• Fussnoten: Gesehen am 10.01.2023
• Titel Quelle: Enthalten in: Cancers
• Ort Quelle: Basel : MDPI, 2009
• Jahr Quelle: 2022
• Band/Heft Quelle: 14(2022), 19, Artikel-ID 4635, Seite 1-14
• ISSN Quelle: 2072-6694
• DOI: doi:10.3390/cancers14194635
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: immunotherapy
• Sach-SW: oral squamous cell carcinoma (OSCC)
• Sach-SW: sTREM2
• Sach-SW: TREM2
• Sach-SW: tumor microenvironment (TME)
• Sach-SW: tumor-associated macrophages (TAMs)
• K10plus-PPN: 1830657143

Abstract

Triggering receptor expressed on myeloid cells 2 (TREM2) is suggested to hamper antitumor immune response in multiple cancers. However, the role of TREM2 in oral squamous cell carcinoma (OSCC) and its expression in tumor-associated macrophages (TAMs) are unknown. In this study, TREM2 expression was analyzed in the primary tumors and corresponding lymph-node metastases of OSCC patients via immunohistochemistry on tissue microarrays. Human peripheral blood mononuclear cells (PBMCs) and single-cell suspensions of tumor and healthy adjacent tissues were analyzed for the presence of TREM2+ macrophages and TAMs using flow cytometry. The serum levels of soluble TREM2 (sTREM2) were quantified using an enzyme-linked immunosorbent assay. High TREM2 expression was associated with advanced UICC stages (Spearman’s rank correlation (SRC), p = 0.04) and significantly reduced survival rates in primary tumors (multivariate Cox regression, progression-free survival: hazard ratio (HR) of 2.548, 95% confidence interval (CI) of 1.089-5.964, p = 0.028; overall survival: HR of 2.17, 95% CI of 1.021-4.613, p = 0.044). TREM2 expression was significantly increased in the PBMCs of OSCC patients in UICC stage IV compared with healthy controls (ANOVA, p < 0.05). The serum levels of sTREM2 were higher in advanced UICC stages, but they narrowly missed significance (SRC, p = 0.059). We demonstrated that TREM2 was multi-factorially associated with advanced stages and inferior prognosis in OSCC patients and that it could serve as a prognostic biomarker in OSCC patients. Targeting TREM2 has the potential to reshape the local and systemic immune landscape for the potential enhancement of patients’ prognosis.